Marseille-based Tafalgie Therapeutics is a biopharmaceutical research company focused on developing new treatments for chronic pain. Founded in 2020 as a spin-off from CNRS and AMU, the company utilizes a breakthrough mechanism of action derived from a naturally occurring protein to modulate pain signals. Their research aims to provide relief for patients suffering from conditions such as migraine, muscle pain, and neuropathies, offering potential analgesic solutions for chronic postoperative and neuropathic pain.